Publicação
SLE-DAS remission and low disease activity states discriminate drug from placebo and better health-related quality of life
| dc.contributor.author | Jesus, Diogo | |
| dc.contributor.author | Henriques, Carla | |
| dc.contributor.author | Matos, Ana | |
| dc.contributor.author | Doria, Andrea | |
| dc.contributor.author | Inês, Luís S. | |
| dc.date.accessioned | 2026-04-14T08:28:21Z | |
| dc.date.available | 2026-04-14T08:28:21Z | |
| dc.date.issued | 2024-01-22 | en_US |
| dc.date.updated | 2026-04-13T18:17:47Z | |
| dc.description.abstract | Objective. Our objective was to evaluate the ability of Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) remission and low disease activity (LDA) to discriminate active drug from placebo and to discriminate outcomes in the patients’ perspective (health-related quality of life [HR-QoL]) in SLE trials. Methods. This was a post hoc analysis of the pooled Belimumab in Subjects With SLE (BLISS)-52 (NCT00424476) and BLISS-76 (NCT00410384) trials data. SLE-DAS remission and LDA attainment and discrimination between belimumab and placebo at 52 weeks were compared using chi-square tests. At week 52, 36-item Short Form Health Survey (SF-36) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scores were compared between patients attaining SLE-DAS remission versus nonremission and SLE-DAS LDA versus non-LDA using the ttest and Mann-Whitney test. Mean changes from week 0 to 52 in SF-36 and FACIT-F scores were compared between groups using multivariate regression analysis adjusted for baseline scores. Results. At week 52, significantly more patients attained SLE-DAS LDA taking belimumab 1 mg/kg (17.9% vs 13.0%; P = 0.023; odds ratio [OR] 1.459; relative risk [RR] 1.377; number needed to treat [NNT] 20.4) and 10 mg/kg (21.7% vs 13.0%; P < 0.001; OR 1.853; RR 1.668; NNT 11.5) compared with placebo. Likewise, more patients attained SLE-DAS remission taking belimumab 10 mg/kg compared to placebo (14.7% vs 10.1%; P = 0.019; OR 1.532; RR 1.454; NNT 21.7). At week 52, patients attaining SLE-DAS remission and LDA presented higher SF-36 domain and summary scores (all P < 0.001) and FACIT-F scores (both P < 0.001). Mean improvements from baseline in SF-36 and FACIT-F scores were significantly higher in patients achieving SLE-DAS remission and LDA. Conclusion. SLE-DAS remission and LDA showed discriminant ability for identifying patients receiving active drug in SLE clinical trials. Attainment of these SLE-DAS targets are associated with better HR-QoL. | por |
| dc.description.version | info:eu-repo/semantics/acceptedVersion | |
| dc.identifier.doi | 10.1002/acr.25305 | en_US |
| dc.identifier.issn | 2151-464X | en_US |
| dc.identifier.issn | 2151-4658 | en_US |
| dc.identifier.slug | cv-prod-3687459 | |
| dc.identifier.uri | http://hdl.handle.net/10400.19/9767 | |
| dc.language.iso | N/A | por |
| dc.title | SLE-DAS remission and low disease activity states discriminate drug from placebo and better health-related quality of life | en_US |
| dc.type | research article | en_US |
| dspace.entity.type | Publication | |
| oaire.citation.title | Arthritis Care & Research | en_US |
| person.familyName | Henriques | |
| person.familyName | Matos | |
| person.givenName | Carla | |
| person.givenName | Ana | |
| person.identifier.ciencia-id | F91C-B000-9ED8 | |
| person.identifier.ciencia-id | 961C-1FBD-5555 | |
| person.identifier.orcid | 0000-0002-2142-2849 | |
| person.identifier.orcid | 0000-0001-6408-5857 | |
| person.identifier.scopus-author-id | 8955187400 | |
| person.identifier.scopus-author-id | 8506082100 | |
| rcaap.cv.cienciaid | F91C-B000-9ED8 | Carla Manuela Ribeiro Henriques | |
| rcaap.rights | closedAccess | en_US |
| relation.isAuthorOfPublication | 9138da60-0a34-4302-b547-864d612c30b8 | |
| relation.isAuthorOfPublication | 69997266-781a-4811-ab7b-5282d69b00e6 | |
| relation.isAuthorOfPublication.latestForDiscovery | 9138da60-0a34-4302-b547-864d612c30b8 |